Calumet, Inc. reported that subsidiaries Calumet Specialty Products Partners, L.P. and Calumet Finance Corp. issued $405.0 million of new 9.75% Senior Notes due 2031 in a private Rule 144A/Reg S offering. The notes were sold at 98.996% of par, generating approximately $393.0 million in net proceeds after discounts and expenses.
The company plans to use these proceeds, along with cash on hand and borrowings under its revolving credit facility, to redeem all outstanding 11.00% Senior Notes due 2026 and 8.125% Senior Notes due 2027, with redemptions expected on or before January 21, 2026. The new notes mature on February 15, 2031, pay interest semi-annually, carry senior unsecured guarantees from the parent and most subsidiaries, and include customary covenants, change-of-control repurchase rights at 101%, and specified call premiums starting in 2028.
Calumet, Inc. reported that its affiliates Calumet Specialty Products Partners, L.P. and Calumet Finance Corp. agreed to sell $405.0 million of 9.75% Senior Notes due 2031 in a private offering under Rule 144A and Regulation S. The notes will be issued at 98.996% of par, providing approximately $393.0 million in net proceeds after discounts and estimated expenses, and are expected to close on January 12, 2026, subject to customary conditions.
The company plans to use the net proceeds, along with cash on hand and borrowings under its revolving credit facility, to redeem all outstanding 11.00% Senior Notes due 2026 and 8.125% Senior Notes due 2027 on or before January 21, 2026, thereby addressing these upcoming debt maturities.
Calumet, Inc. announced that its wholly owned subsidiaries, Calumet Specialty Products Partners, L.P. and Calumet Finance Corp., intend to offer $350.0 million in aggregate principal amount of senior unsecured notes due 2031 in a private placement to eligible purchasers. Calumet plans to use the net proceeds from the new notes, together with cash on hand and borrowings under its revolving credit facility, to redeem all of its outstanding 11.00% Senior Notes due 2026 on or around January 21, 2026 and $275.0 million of its outstanding 8.125% Senior Notes due 2027 on or around January 16, 2026. The notes will not be registered under the Securities Act or state securities laws and may only be offered and sold in the United States pursuant to an applicable registration exemption.
Calumet, Inc. filed a current report noting that it has issued a press release with preliminary, unaudited information about its liquidity and select fiscal year 2025 financial results. The press release is attached as an exhibit to the report and is incorporated by reference. The company also clarifies that this preliminary financial and liquidity information is being furnished rather than filed, so it is not automatically subject to certain Exchange Act liabilities or included in other securities filings unless specifically cited.
Calumet, Inc. reported that one of its directors acquired 5,053 shares of common stock, par value $0.01 per share, on 12/04/2025 through the settlement of restricted stock units at a price of $0 per share.
After this transaction, the director directly beneficially owned 24,733 shares of Calumet common stock. The related derivative position of 5,053 restricted stock units was reduced to zero as they were fully converted into common stock, with each unit economically equivalent to one share and 100% vested.
Calumet, Inc. reported an insider equity transaction by one of its directors.
On December 4, 2025, the director converted 2,526 restricted stock units into common stock and disposed of 1,011 common shares. After these transactions, the director beneficially owns 28,793 shares of Calumet common stock directly. Each restricted stock unit is the economic equivalent of one Calumet common share, is 100% vested, and can be settled in shares or their cash value. The director elected to have 40% of the vested restricted stock units settled in the cash equivalent of a common share.
Calumet (CLMT) reported a Form 4 for a director showing awards of restricted stock units on 11/06/2025. The filing lists 1,281 RSUs (Transaction Code A) at a price of $0 and 427 RSUs (Code A) at a price of $0, both recorded as direct ownership.
The 1,281 RSUs are 100% vested and settle upon the earlier of a specified date or the reporting person’s termination. The 427 RSUs settle under the Deferred Compensation Plan and vest 25% on July 1 of each year beginning July 1, 2026.
Calumet, Inc. (CLMT) reported a director’s equity award activity. On November 6, 2025, the reporting person acquired 384 Restricted Stock Units (RSUs) and 128 RSUs at $0 per unit, reported as direct ownership.
Each RSU equals one share of Calumet common stock. The 384 RSUs are 100% vested and will be settled upon the earlier of a date specified by the reporting person or the reporting person’s termination date. The 128 RSUs, granted under the Deferred Compensation Plan, will be settled upon the earlier of a specified date or termination, with 25% vesting each July 1 beginning July 1, 2026.
Calumet, Inc. (CLMT) disclosed a Form 4 showing a director received two Restricted Stock Unit awards on 11/06/2025. The filings list 1,761 RSUs (100% vested, to be settled upon the earlier of a specified date or termination) and 587 RSUs (under the Deferred Compensation Plan, vesting 25% each July 1 beginning July 1, 2026). Both derivative positions are shown as Direct (D) ownership at a price of $0 per unit.
Calumet, Inc. (CLMT) reported a routine insider equity event. A director filed a Form 4 showing two grants of restricted stock units on 11/06/2025: 1,172 RSUs and 390 RSUs, each acquired at $0 and held directly. Each RSU represents the economic equivalent of one share of Calumet common stock.
The filing notes distinct settlement and vesting terms. The 1,172 RSUs are 100% vested and settle upon the earlier of a date specified by the reporting person or their termination date. The 390 RSUs, granted under a Deferred Compensation Plan, settle on the same trigger, with 25% vesting on July 1 of each year beginning July 1, 2026.